A double-edged sword of using opioids and COVID-19: a toxicological view.
COVID-19
Immune system
Opioids
Prognosis
Journal
Substance abuse treatment, prevention, and policy
ISSN: 1747-597X
Titre abrégé: Subst Abuse Treat Prev Policy
Pays: England
ID NLM: 101258060
Informations de publication
Date de publication:
03 12 2020
03 12 2020
Historique:
accepted:
23
11
2020
entrez:
4
12
2020
pubmed:
5
12
2020
medline:
29
12
2020
Statut:
epublish
Résumé
Today, COVID-19 is spreading around the world. Information about its mechanism, prognostic factors, and management is minimal. COVID-19, as a human disease, has several identifying phases. Physicians of patients with COVID-19 may be interested in knowing whether opioid use disorder may affect their patients' course or prognosis. This information may be crucial when considering the opioid epidemic in the US and other parts of the world. Opioid use at high doses and over several months duration can mitigate the immune system's function, which may complicate the course of COVID-19 disease. Potential suppression of parts of the immune response may be important in prevention, clinical support, and therapeutic use of medications in various phases of the COVID-19. Specifically, opioid use disorders via an inhalation route may enhance the "late hyper-inflammatory phase" or result in end-organ damage. It is well established that opioids decrease ventilation as their effect on the medullary respiratory centers increases the risk of pneumonia. This increased risk has been associated with immune-suppressive opioids. The ultimate role of opioids in COVID-19 is not clear. This paper endorses the need for clinical studies to decipher the role and impact of chronic opioid use on viral diseases such as COVID-19.
Identifiants
pubmed: 33272308
doi: 10.1186/s13011-020-00333-y
pii: 10.1186/s13011-020-00333-y
pmc: PMC7711252
doi:
Types de publication
Letter
Langues
eng
Sous-ensembles de citation
IM
Pagination
91Références
Eur J Clin Microbiol Infect Dis. 2020 Oct;39(10):2001-2002
pubmed: 32557325
J Infect Dis. 2016 Mar 15;213(6):877-9
pubmed: 26203059
J Clin Virol. 2020 Jun;127:104371
pubmed: 32315817
J Infect Dis. 2014 May 1;209(9):1331-42
pubmed: 24065148
Diabetes Metab Syndr. 2020 Sep - Oct;14(5):817-823
pubmed: 32540735
Lancet. 2020 Feb 15;395(10223):e30-e31
pubmed: 32032529
Mol Psychiatry. 2020 Sep 30;:
pubmed: 32999436
Br J Anaesth. 2013 Jul;111(1):80-8
pubmed: 23794649
Trop Med Int Health. 2020 Mar;25(3):278-280
pubmed: 32052514
Physiol Rev. 2020 Oct 1;100(4):1455-1466
pubmed: 32496872
Br J Anaesth. 2019 Jun;122(6):e168-e179
pubmed: 30915997
Am J Med. 1950 Aug;9(2):186-93
pubmed: 15432465
Lancet. 2020 Mar 28;395(10229):1033-1034
pubmed: 32192578
Immunol Lett. 2013 Apr;152(1):42-6
pubmed: 23603301
Microbes Infect. 2020 Mar;22(2):72-73
pubmed: 32092539
Arch Immunol Ther Exp (Warsz). 2008 Sep-Oct;56(5):299-309
pubmed: 18836861
Psychopharmacology (Berl). 2005 May;179(3):700-4
pubmed: 15806416
Respirology. 2018 Feb;23(2):130-137
pubmed: 29052924
J Addict Med. 2020 Jul/Aug;14(4):e6-e7
pubmed: 32404651
Front Immunol. 2019 Dec 12;10:2914
pubmed: 31921173
Diabetes Metab Syndr. 2020 Jul - Aug;14(4):637-639
pubmed: 32428864
J Gen Intern Med. 2020 Nov;35(11):3315-3322
pubmed: 32885375
Virology. 2014 Apr;454-455:197-205
pubmed: 24725946
Eur Cytokine Netw. 2007 Dec;18(4):210-4
pubmed: 17993452
Curr Opin Support Palliat Care. 2008 Mar;2(1):14-8
pubmed: 18685388
Am J Hosp Palliat Care. 2003 Jan-Feb;20(1):57-61
pubmed: 12568438
Ann Intern Med. 2020 Jul 7;173(1):61-62
pubmed: 32240293
Vet J. 2014 May;200(2):270-5
pubmed: 24679456
Brain Behav Immun. 2008 May;22(4):606-13
pubmed: 18294814
Genome Biol. 2004;5(12):253
pubmed: 15575979
Expert Rev Respir Med. 2020 Oct;14(10):965-967
pubmed: 32576053
Lancet. 2003 Apr 19;361(9366):1319-25
pubmed: 12711465
Br J Anaesth. 2020 Oct;125(4):e382-e383
pubmed: 32768181
Neurochem Res. 1996 Nov;21(11):1375-86
pubmed: 8947928